Drug intelligence / Profile preview

TOR-105

Development stage: Preclinical
Lead developer: Tornado Therapeutics
Modality: Small Molecules

Overview

TOR-105 is a small molecule drug under development by Tornado Therapeutics for dermatological applications, specifically targeting skin and musculoskeletal diseases. Its primary active indication is onycholysis, a condition characterized by the detachment of the nail from the nail bed. As of May 2025, TOR-105 remains in preclinical development and has not yet entered clinical trials. The precise mechanism of action and molecular targets have not been publicly disclosed[1][2][4].

Targets

Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on TOR-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOR-105.

Explore the full profile